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Abstract The dopamine D3 receptor is a member of the G
protein-coupled superfamily of receptors. However, its coupling
with intracellular events is still not well understood. We have
performed chimera constructions in which amino acid residues
located in a region of the receptor involved in the coupling with
second messengers (the C-terminal portion of the third intracel-
lular loop) have been exchanged between dopamine D2 and D3
receptors. Chimera constructions did not modify substantially the
pharmacological profiles, nor G protein coupling, as compared to
their respective wild-type receptors. However, the D2 receptor
chimera, containing the C-terminal portion of the third
intracellular loop of the D3 receptor, has a lower potency to
inhibit cyclic AMP production. The reciprocal construction
generated a D3 receptor that is fully coupled to this second
messenger pathway whereas, the native D3 receptor is uncoupled
to this pathway in our transfected cells. These results suggest
that the sequence selected is important for specific coupling
characteristics shown by these two dopamine receptor homo-
logues.
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1. Introduction
Dopamine receptors are members of the superfamily of G
protein-coupled receptors. On the basis of their genetic organ-
ization, pharmacology and intracellular signaling properties,
they are divided into two subgroups, termed D1-like (which
include D1 and D5 subtypes) and D2-like (including D2, D3
and D4 subtypes) receptors [1]. Among these various sub-
types, the D3 receptor displays properties which suggest that
it may represent a target for antipsychotic drugs [2]. The D3
receptor has a large third intracellular loop and a short C-
terminal tail, which are typical of G protein-coupled receptors
that interact with a Go/GiK protein and mediate the inhibition
of adenylate cyclase (AC) activity. However, coupling of the
D3 receptor with inhibition of cyclic AMP (cAMP) produc-
tion has not been clearly demonstrated [2^9]. On the other
hand, in some heterologous expression systems, D3 receptor
can couple with various second messenger systems, including
inhibition of cAMP production [10^12], ion channel activity
or stimulation of Na/H exchange [6,10,13,14], or to pro-
duce intracellular responses, such as increased mitogenesis
[5,10,15] or stimulation of Fos-like immunoreactivity [5].
Whether these coupling pathways of the receptor represent
true natural interactions or are artifacts, because of high levels
of receptors in heterologous expression systems, remains a
matter of controversy.
The modulation of agonist binding to the D3 receptor by
guanosine triphosphate nucleotide (GTP), an indicator of re-
ceptor/G protein interactions, is most of the time not observed
[2,9,16]. When observed, this GTP shift, as it is called, is very
weak, as compared to other Gi-coupled receptors, such as the
D2 receptor [5,8,10,16]. Interestingly, a similar weak GTP
shift is also observed in tissue homogenates from lobules IX
and X of the rat cerebellum, where the D3 receptors is the
only representative of the D2-like receptor subgroup [17].
Thus, it is possible that the relative absence of GTP shift is
an intrinsic property of the D3 receptor. Recently, a coupling
of the D3 receptor with the type V isoform of AC, but
not type II, has been observed [18,19]. But again, activation
of GiK subunits, as measured by agonist-induced guanosine
5P[Q-thio]triphosphate-[35S] ([35S]GTPQS) binding, is quite
low, as compared to D2 receptor-mediated e¡ect in similar
conditions [18].
Investigations of the coupling of D3 receptors have also
been performed using D2/D3 receptor chimera constructions
[20^22]. These studies indicate that the third intracellular loop
of D2 and D3 receptors is important for the coupling to AC.
Moreover, in D3/D2 receptor chimeras that fully coupled to
inhibition of cAMP production, agonist binding to these chi-
meras is still resistant to the e¡ect of GTP or its analogues
[23]. We undertook the present study in order to identify more
speci¢c components of the third intracellular (i3) loop of hu-
man dopamine D2 (hD2) and D3 (hD3) receptor subtypes
involved in the coupling of these receptors with AC. We
have studied a sketch of 12 divergent amino acid residues
located at the C-terminal portion of the i3 loop of these re-
ceptors (Fig. 1). Reciprocal chimera constructions between
hD2 and hD3 dopamine receptors using this amino acid seg-
ment produce minimal e¡ects in the pharmacological pro¢les
of the chimera receptors, as compared to their respective wild-
type receptors, but a¡ect the coupling of these receptors with
AC activity.
2. Materials and methods
2.1. Materials
[3H]Spiperone was purchased from Amersham Life Science (Oak-
ville, Ont., Canada). 5P-Guanylylimidodiphosphate (Gpp(NH)p), for-
skolin and isobutylmethylxanthine (IBMX) are from Sigma-Aldrich
(Oakville, Ont., Canada). Antagonists (+)butaclamol, clozapine, hal-
operidol, raclopride and risperidone, as well as agonists quinpirole,
R(+)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (R(+)7-OH-DPAT),
bromocriptine, apomorphine and pergolide were from Research Bio-
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chemicals International (RBI, Natick, MA, USA). Cyclic AMP levels
were measured using the Rianen [125I]cAMP radioimmunoassay kit
purchased from DuPont NEN (Guelph, Ont., Canada). Cell culture
media Dulbecco’s modi¢ed Eagle medium (DMEM) and F12, as well
as certi¢ed fetal bovine serum were obtained from Gibco BRL (Life
Sciences Technologies, Burlington, Ont., Canada).
2.2. Cell lines and chimera constructions
The construction and stable transfection of hD2 [24], hD3 receptor
[25] and receptor chimeras were performed in Chinese hamster ovary
(CHO) cells. Cell lines were maintained in Ham’s F12 medium sup-
plemented with L-glutamine (0.3 mg/ml), 10% heat-inactivated fetal
bovine serum, 100 U/ml penicillin and 100 Wg/ml streptomycin at
37‡C and 5% CO2. DNA transfections into CHO cells were performed
with the calcium/phosphate method in standard conditions. Chimeras
were constructed using polymerase chain reaction (PCR) technology.
Subcloning of the hD3 receptor into the mammalian expression vector
pRC/CMV containing a resistance gene for neomycin (G418, Gibco
BRL) was previously described [5]. To introduce the hD2 receptor
peptide, corresponding to amino acid 327^ 338 (KTMSRRKLSQQK)
of the C-terminal portion of the i3 loop (Fig. 1), into the hD3 recep-
tor, two PCR reactions were combined. One set of primers containing
the initiation ATG codon of the hD3 receptor (with a HindIII site)
and overlapping sequences of hD2 and hD3 receptors were synthesized
(sense: 5P-ACGAAGCTTATGGCATCTCTGAGTCAGCTGA-3P
and antisense: 5P-CTTACGTCGACTCATGGTCTTCAAAGATGT-
CGATAA-3P). A second set of primers were synthesized in order to
obtain the remaining portion of the hD3 receptor sequence (sense: 5P-
CATGAGTCGACGTAAGCTCTCCCAGCAGAAGGAGAAGAA-
GGCAACCCAAATGGTG-3P and antisense 5P-TGCAGATCTT-
CAGCAAGACAGGATCTTGAGG-3P, containing the stop codon
and a XbaI site). The degenerate nature of trinucleotide codons for
amino acid residues serine and arginine was exploited to generate a
SalI restriction site (nucleotide sequences underlined) in the middle of
the sequence corresponding to the segment of the hD2 receptor to be
introduced in the hD3 receptor. Ampli¢ed PCR fragments were then
digested with corresponding sets of endonuclease restriction enzymes
(HindIII/SalI and SalI/XbaI), ligated and introduced into the poly-
linker of a pRC/CMV plasmid (HindIII/XbaI) to form the hD3 recep-
tor chimera with the C-terminal portion of the i3 loop of the hD2
receptor (named hD3/hD2i3). Similar experiments were performed to
construct the reciprocal hD2 chimera, where a hD3 receptor peptide
sequence, corresponding to amino acid 312^323 (LGPLQPRGVPLR)
of the C-terminal portion of the i3 loop of the receptor is introduced
into the reading frame of the hD2 receptor (Fig. 1). This chimera is
named hD2/hD3i3. For this construction, we started with a hD2 (short
isoform) subcloned into a pCMV5 plasmid (a gift from Dr. Pierre
Falardeau). The ¢rst set of primers included a hD2 ATG primer
with an EcoRI site (5P-TGCGAATTCGCCACCATGGATCCACT-
GAAT-3P) and the antisense primer in the third intracellular loop
containing a KspI (SacII, underlined) site (5P-ACTCCCCGCGGTT-
GCAGGGGCCCCAGGGAGGTCCGGGTTTTGCCATTGGG-3P),
the second set of primer consisted to a sense primer containing a KspI
site (5P-CCTGCAACCGCGGGGAGTGCCACTTCGGGAGAA-
GAAAGCCACTCAGATGCTT-3P) and antisense primer containing
a KpnI site and a stop codon (5P-CATGGTACCTCAGCAGTG-
GAGGAT-3P). Again, the KspI site was introduced by using the de-
generative nature of trinucleotide codons for the amino acid proline
and arginine. After digestion with appropriate restriction enzymes, the
resulting hD2 receptor chimera containing a segment of the i3 loop of
the hD3 receptor was subcloned into the pRC/CMV expression vec-
tor. All the constructions were sequenced using Sequenase Version 2.0
DNA sequencing kit (USB, Cleveland, OH, USA) to verify the se-
quences.
2.3. Binding assay
Con£uent cells were trypsinized, resuspended in F12 medium and
rapidly centrifuged at 2000Ug for 5 min. They were homogenized
using a polytron (at moderate velocity) and resuspended in a Tris-
HCl bu¡er (15 mM) containing 5 mM MgCl2, pH 7.4, then recentri-
fuged at 50 000Ug for 15 min. Incubation bu¡er contained 50 mM
Tris-HCl, 120 mM NaCl and 5 mM MgCl2, pH 7.4. [3H]Spiperone
(speci¢c activity: 94^107 Ci/mmol) binding was performed. For iso-
therm saturation experiments increasing concentrations (0.01^3 nM)
of [3H]spiperone were added to the incubation bu¡er. The reaction
was started by addition of cell homogenates (20^50 Wg of protein
determine by the method of Lowry [26]) in a ¢nal volume of 1 ml.
(+)Butaclamol (1 WM) or raclopride (1 WM) was used to determine
non-speci¢c binding for hD2 or hD3 receptors or respective receptor
chimeras constructions. Incubations lasted for 1 h at room temper-
ature and were stopped by rapid ¢ltration through GF/C ¢lters
(Whatman) with ice-cold Tris-NaCl bu¡er. 10 ml of scintillation cock-
tail was added to the ¢lters and radioactivity was counted at 30%
e⁄ciency. Competitions of [3H]spiperone binding (0.8^1.0 nM) with
agonists and antagonists were performed in similar conditions. For
GTP-induced shift of dopamine a⁄nities, Gpp(NH)p (100 WM) was
added. Each concentration points were performed in triplicate. Com-
puter assisted non-linear regression curve analysis were performed
using the GraphPad software (Prism 2.0, GraphPad Software Inc.)
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Fig. 1. Schematic representation of the dopamine hD2 and hD3 se-
quences (shaded circles) that were used for chimera constructions.
The diagram illustrates the C-terminal portion of the third intracel-
lular loop of the hD3 receptor with the transmembrane domain VI
(TMVI). The one letter code for amino acid residues is used. Recip-
rocal chimera constructions were performed (see Section 2) where
the represented sequence of the hD3 receptor was replaced by the
hD2 receptor sequence and vice et versa (chimeras are named hD3/
hD2i3 and hD2/hD3i3, respectively).
Table 1
Pharmacological pro¢le of dopamine receptor chimera constructions compared to the human D2 and D3 wild-type receptor subtypes
hD2 hD2/hD3i3 hD3 hD3/hD2i3
Agonists
Quinpirole 1708 þ 961 1124 þ 473 7.9 þ 3.0 14.9 þ 3.9
Pergolide 24 þ 6 37 þ 11 0.5 þ 0.1 1.7 þ 0.3
Apomorphine 83 þ 34 123 þ 33 24 þ 4 33 þ 3
R(+)7-OH-DPAT 313 þ 88 270 þ 25 0.6 þ 0.1 1.3 þ 0.2
Bromocriptine 10.4 þ 4.7 7.9 þ 1.4 2.5 þ 0.3 4.9 þ 0.9
Antagonists
Haloperidol 1.0 þ 0.2 0.6 þ 0.1 1.0 þ 0.3 1.0 þ 0.4
Raclopride 2.3 þ 0.6 2.0 þ 0.5 1.5 þ 0.4 1.4 þ 0.1
Clozapine 477 þ 114 437 þ 66 371 þ 123 380 þ 53
Risperidone 4.1 þ 0.6 3.6 þ 0.9 11.4 þ 2.2 10.3 þ 0.6
Values represent means þ S.E.M. of inhibition constants (Ki) expressed in nM (n = 3^5).
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and each set of data were successively ¢tted according to a one- or a
two-site binding model. Then the ¢ts were statistically compared and
a two-site model was retained only if it was statistically better
(P6 0.05) than the one-site analysis.
2.4. Cyclic AMP assay
Cells were plated in 96-well plates at a density of 40 000 cells/well.
After 24 h culture, cells were washed twice for 15 min with 0.2 ml of
DMEM without serum at 37‡C and 5% CO2. Cells were then incu-
bated in ¢ve replicates for 15 min at 37‡C in 5% CO2 with increasing
concentration of dopamine (0.1 nM^10 WM) in the presence of 100
WM IBMX and 10 WM forskolin in a ¢nal volume of 0.15 ml of
DMEM (forskolin and dopamine were omitted to determine basal
cAMP levels). Then, the medium containing the drugs was rapidly
removed and 50 Wl/well of 0.1 N HCl was added, and the plates
were placed on ice. Cells were sonicated for 5 s and the extract was
neutralized with 0.4 ml of a mixture of 2.4 M sodium acetate, pH 6.0,
and 2 N NaOH. Cyclic AMP levels were measured using the Rianen
[125I]cAMP radioimmunoassay kit from DuPont NEN (Guelph, Ont.,
Canada) in the conditions recommended by the manufacturer.
2.5. Statistical analysis
The data were compared using an analysis of variance (one-way
ANOVA), followed by a Fisher probability of least signi¢cant di¡er-
ence (PLSD) test.
3. Results
Among all the positive clones selected in our transfection
experiments we only kept a series of clones that expressed
similar levels of dopamine hD2, hD3, hD2/hD3i3 and hD3/
hD2i3 receptors (maximal receptor capacities (Bmax) were:
hD2, 364 þ 81; hD3, 438 þ 84; hD2/hD3i3, 370 þ 13 and hD3/
hD2i3, 366 þ 42 fmol/mg of protein, n = 5). The hD2 and hD3
receptor chimeras have similar equilibrium dissociation con-
stant (Kd), as compared to their respective wild-type homo-
logues (Kd were: hD2, 80 þ 20; hD3, 107 þ 17; hD2/hD3i3,
93 þ 30 and hD3/hD2i3, 99 þ 9 pM, n = 5). Comparisons of in-
hibitory constants (Ki) for dopamine agonists and antagonists
indicate that the pharmacological pro¢les shown by hD2/
hD3i3 and hD3/hD2i3 receptor chimeras are quite similar to
their respective wild-type receptors (Table 1). Overall, binding
of agonists is not a¡ected in the hD2/hD3i3 chimera, as com-
pared to the hD2 receptor, whereas binding a⁄nities of ago-
nists are slightly (2-fold) decreased in the hD3/hD2i3 chimera,
as compared to the hD3 receptor (Table 1). However, com-
pounds which display selectivity for a receptor subtype, such
as R(+)7-OH-DPAT for the D3 receptor, maintained their
selectivity (Table 1 and Fig. 2). Binding of antagonists is
not a¡ected in any cases (Table 1).
Interaction of G protein-coupled receptors with heterotri-
meric G proteins can be indirectly visualized by the GTP-
induced shift of the high a⁄nity state into the low a⁄nity
state for the endogenous ligand. As expected, we observed a
high and low a⁄nity states for the hD2 receptor. Addition of
Gpp(NH)p, a non-hydrolyzable analogue of GTP, induced a
complete conversion of the high a⁄nity into the low a⁄nity
state of the hD2 receptor for dopamine (Table 2). For the hD3
receptor, in most experiments, we were not able to observe
high and low a⁄nity states for dopamine in our transfected
cells (Table 2). However, in three experiments out of eight, we
did see a better ¢t with the two-site model (see Fig. 3). When
observed, the high a⁄nity state of the hD3 receptor was never
converted into a low a⁄nity state in the same conditions
(neither with higher Gpp(NH)p concentrations, data not
shown). Although the high a⁄nity state of the hD3 is similar
to the value of the hD2 receptor, the fraction of the total hD3
receptor number in this state is more important than the hD2
receptor (Table 2). Moreover, the low a⁄nity state of the hD3
receptor is only 10-fold lower than the high a⁄nity state of
the receptor, whereas it is about 1000-fold lower for the hD2
receptor (Table 2). The hD2/hD3i3 receptor chimera also dis-
played a complete conversion of the high a⁄nity state for
dopamine into a low a⁄nity state, but the high a⁄nity state
for dopamine was lower, whereas the proportion of the total
receptor population in the high a⁄nity state is higher in this
receptor chimera, as compared to the wild-type hD2 receptor
(Table 2 and Fig. 3). All the hD3/hD2i3 receptor chimera bind-
ing parameters were identical to the wild-type hD3 receptor
(Table 2). However, in three GTP shift experiments out of
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Fig. 2. Representative examples of displacement curves obtained
from the competition of [3H]spiperone binding (0.8^1.0 nM) with
various agonists and antagonists (competition with R(+)-7-OH-
DPAT is presented) with wild-types and chimera constructions. In-
hibitory constants (Ki) were calculated from half-maximal inhibitory
concentration values (IC50) according to the Cheng and Pruso¡ cor-
rection: Ki = IC50/(1+[L]/Kd), where L and Kd are the concentration
and the dissociation constant of the radiolabeled ligand used, re-
spectively [38].
Table 2
GTP-induced a⁄nity shifts of dopamine for receptor chimera constructions compared to the human D2 and D3 wild-type receptor subtypes
CHO cell types expressing human dopamine receptors
hD2 hD2/hD3i3 hD3 hD3/hD2i3
Dopamine Kh (nM) 5.5 þ 2.5 17.2 þ 5.5* 4.1 þ 1.3 3.9 þ 1.3
KL (nM) 3800 þ 1200 2510 þ 670 (74 þ 6) (54 þ 28)
Rh (%) 29.6 þ 5.3 47.1 þ 13.7 (66.4 þ 1.4)* (84.6 þ 6.2)
Dopamine+Gpp(NH)p Kh (nM) ^ ^ ^ ^
KL (nM) 2460 þ 640 2400 þ 700 7.7 þ 1.6 6.5 þ 1.4
Values represent means þ S.E.M. (n = 6^8).
*P6 0.05 vs. hD2 receptor. Values presented in parentheses were obtained in three out of eight experiments with hD3 and hD3/hD2i3 receptors. See
Fig. 3 for additional information.
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seven, we observed a small but signi¢cant GTP shift with the
hD3/hD2i3 receptor chimera (see Fig. 3). The reasons for the
variability of GTP e¡ects in hD3 receptor constructions is still
not clear for the moment.
Despite the fact that apparent coupling with G proteins (as
observed with the GTP shift) is not greatly a¡ected in the
chimeras, coupling to AC was dramatically modi¢ed (Figs.
4 and 5). The hD2/hD3i3 receptor chimera showed a 3-fold
decrease in the IC50 of dopamine for inhibition of forskolin-
stimulated cAMP levels (Figs. 4 and 5A), as compared to the
hD2 receptor, whereas its maximal response was increased
(Figs. 4 and 5B). Although the native hD3 receptor is not
coupled to cAMP pathway in our transfected CHO cell lines,
the hD3/hD2i3 receptor chimera construction was fully
coupled with AC (even with a higher potency than the hD2
receptor) (Figs. 4 and 5A). However, the maximal capacity for
dopamine to inhibit forskolin-stimulated cAMP levels with
the hD3/hD2i3 receptor chimera is lower than that of the
hD2 or hD2/hD3i3 receptors (Figs. 4 and 5B). Basal levels of
cAMP were similar for all hD2 and hD3 wild-type and mutant
receptors (hD2, 1.2 þ 0.3; hD3, 2.3 þ 1.1; hD2/hD3i3, 1.7 þ 0.5
and hD3/hD2i3, 2.1 þ 0.4 pmol/ml). However, forskolin-stimu-
lated cAMP level (at 10 WM) was signi¢cantly higher in the
hD3/hD2i3 chimera, as compared to the other constructions
(hD2, 123 þ 11; hD3, 110 þ 22; hD2/hD3i3, 110 þ 13 and hD3/
hD2i3, 192 þ 23 pmol/ml, P6 0.01). A dose-response curve of
forskolin for stimulation of cAMP production was performed.
No di¡erence in the EC50(s) of forskolin to stimulate cAMP
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Fig. 3. Representative examples of the competition of [3H]spiperone binding by dopamine in the absence or presence of Gpp(NH)p (100 WM)
with dopamine hD2 and hD3 wild-type receptors and hD2/hD3i3 and hD3/hD2i3 receptor chimera constructions. Values are: hD2 control,
Kh = 3.3 nM, KL = 998 nM, Rh = 22.6%; hD2 Gpp(NH)p, KL = 860 nM; hD3 control, Kh = 5.2 nM, KL = 88 nM, Rh = 34.4%; hD3 Gpp(NH)p,
KL = 11 nM; hD2/hD3i3 control, Kh = 3.4 nM, KL=59 nM, Rh = 61.6%; hD2/hD3i3 Gpp(NH)p, KL = 50 nM; hD3/hD2i3 control, Kh = 2.8 nM,
KL = 158 nM, Rh = 78.5%; hD3/hD2i3 Gpp(NH)p, KL = 12 nM. For the hD3/hD2i3 chimera, the example illustrated here is taken from an experi-
ment where a high and low a⁄nity states (two-site model), as well as a signi¢cant GTP shift were observed (see Table 2).
Fig. 4. Representative examples of the inhibition of forskolin-stimu-
lated (10 WM) cAMP levels by increasing concentration of dopamine
with hD2, hD3, hD2/hD3i3 and hD3/hD2i3 receptors stably trans-
fected in CHO cells. Half-maximal inhibitory concentrations (IC50)
and maximal responses (MR) values for this exemple are: hD2,
IC50 = 19 nM, MR = 72.2%; hD2/hD3i3, IC50 = 55 nM, MR = 93.3%;
hD3, not coupled; hD3/hD2i3, IC50 = 1.5 nM, MR = 57.0%. Means
þ S.E.M are presented in Fig. 5.
F. Filteau et al./FEBS Letters 447 (1999) 251^256254
production was observed between dopamine wild-types and
chimera receptor clones (data not shown).
4. Discussion
Results presented clearly indicate that the amino acid
sketch selected for the construction of the chimeras is ex-
tremely important in the coupling characteristics showed by
dopamine hD2 and hD3 receptors. Reciprocal replacements of
the selected C-terminal amino acid segment of the i3 loop of
these receptors induced minimal modi¢cations of pharmaco-
logical pro¢les of the chimeras with only subtle e¡ects on G
protein coupling. However, the potency of the coupling with
AC activity of the hD2/hD3i3 receptor chimera, where the 12
amino acid sequence (see Fig. 1) of the hD2 receptor is re-
placed by the equivalent sequence of the hD3 receptor, was
reduced (decreased dopamine IC50 for inhibition of forskolin-
stimulated cAMP levels), whereas the reciprocal chimera
(hD3/hD2i3) shows an inhibition of AC activity with a high
potency, but with a lower maximal capacity (the hD3 wild-
type was not coupled to AC in our CHO transfected cells).
The main characteristic of the amino acid sketch selected
for construction of the chimeras is that many (9 out of 12
amino acids) amino acid residues carrying charged or polar
groups in the hD2 sequence are replaced at equivalent position
by aliphatic or hydrophobic groups in the hD3 receptor (see
Fig. 1). This sequence has been chosen because we were look-
ing for divergent sequences susceptible to explain the di¡er-
ence in coupling properties between these two dopamine re-
ceptor homologues. Moreover, the £anking sequence
EKKATQ (closed to TMVI) and the N-terminal TSL £anking
residues of this segment are conserved in both receptors (Fig.
1). The K(R)EKKATQ residues have been shown to form a
regulatory region (including the threonine residue and the
BBXB motif, where B is a basic residue) for interaction
with G protein and were shown to have conformational e¡ects
in the production of constitutive activation of the receptors
[27]. The alanine residue (underlined) present in the £anking
region of the segment chosen is equivalent to the alanine
residue which induces constitutive activity of adrenergic re-
ceptors, when mutated [28]. Unsurprisingly, we did not see
any evidence of an increase in constitutive activity in our
receptor chimeras. On the contrary, the higher capacity of
forskolin to stimulated cAMP production in the hD3/hD2i3
chimera and the increase of the maximal response to inhibit
forskolin-stimulated cAMP with the hD2/hD3i3 may suggest
that we in fact have relieved some pre-existing constitutive
activity in both native receptors with the chimera construc-
tions. Results from other sources also suggest that both dop-
amine D2 and D3 receptors may indeed display constitutive
activity. For example, in heterologous expression systems, in-
verse agonist activities of some antagonists have been ob-
served for both receptors [29,30].
The C-terminal portion of the i3 loop of G protein-coupled
receptors has been shown to play a critical role in the coupling
to second messenger systems of various receptor subtypes
[27,31^36], including the D2 receptor [37]. Our data indicate
that this portion in the hD3 receptor sequence may be, on the
contrary, responsible for the absence of coupling with cAMP
in CHO cells, because when replaced with the equivalent hD2
sequence, it induced a coupling with AC activity. We cannot
exclude the possibility that the appropriate G protein, which
normally couples to the hD3 receptor, is not expressed in this
cell line. But, the similarity of GTP shifts observed with D3
transfected cell homogenates and brain tissue homogenates
containing the D3 receptor is striking [17]. Introduction of
the hD3 sequence into the hD2 receptor decrease the a⁄nity
of the high a⁄nity state of the hD2 receptor. This is consistent
with the lower potency of this chimera to inhibit cAMP pro-
duction. Other regions in the hD2 receptor sequence are pos-
sibly involved in the coupling with Gi protein, because we
only see a partial reduction in the potency of the receptor
to inhibit cAMP production, as compared to the lack of e¡ect
of the hD3 receptor. The hD3/hD2i3 receptor chimera is
coupled to inhibition of AC activity with a high potency,
but with a lower maximal capacity, as compared to the hD2
receptor. The potency and maximal response for inhibition of
AC activity observed with the hD3/hD2i3 chimera are similar
to what is reported for the hD3 receptor, when a coupling to
AC activity is observed, in other heterologous expression sys-
tems [10,12].
It has been suggested that the C-terminal portion of the i3
loop located at the junction of TMVI of G protein-coupled
receptor form a short K-helix that is extremely important for
the interaction with heterotrimeric G proteins [33,36]. It is
possible that proline residues (especially the proline residue
at position 321) present in this portion of the i3 loop of the
hD3 receptor disrupt the K-helix structure important for in-
teractions with heterotrimeric G proteins. Thus, despite its
FEBS 21758 22-3-99
Fig. 5. E¡ect of receptor chimera constructions on the potency (A)
and maximal response (B) for inhibition of forskolin-stimulated (10
WM) cAMP levels by dopamine. The results on potency represent
half-maximal inhibitory concentration values (IC50 expressed in nM)
and maximal inhibitory responses (expressed in % of forskolin-
stimulated levels) are means þ S.E.M. obtained from 6^8 independ-
ent determinations. *P6 0.05 and **P6 0.01 vs. hD2 receptor.
NC = not coupled.
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general structural organization that suggests a coupling with
Gi proteins, which leads to inhibition of AC activity, the hD3
receptor may not be coupled with this pathway in physiolog-
ical conditions.
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